Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 234Squamous Cell Carcinoma of Head and Neck 168Head and Neck Neoplasms 141Lung Neoplasms 110Esophageal Neoplasms 109Nasopharyngeal Carcinoma 104Uterine Cervical Neoplasms 101Stomach Neoplasms 88Esophageal Squamous Cell Carcinoma 86Breast Neoplasms 69Urinary Bladder Neoplasms 66Small Cell Lung Carcinoma 58Pancreatic Neoplasms 56Neoplasms 55Carcinoma, Squamous Cell 55Cholangiocarcinoma 52Ovarian Neoplasms 45Neoplasm Metastasis 44Oropharyngeal Neoplasms 43Biliary Tract Neoplasms 41Adenocarcinoma Of Esophagus 35Recurrence 29Mesothelioma, Malignant 28Triple Negative Breast Neoplasms 25Laryngeal Neoplasms 25Nasopharyngeal Neoplasms 24Lymphoma 24Gallbladder Neoplasms 24Sarcoma 21Carcinoma 21

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Resectable Biliary Tract Cancer × Cisplatin × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡